NASDAQ · PGEN
Precigen, Inc.
Healthcare · Biotechnology
$6.19▼ 3.13% ($0.20)at close
After hours$6.22▲ 0.48%7:59 PM ET
Valuation
Revenue & margin DCF
Verdict: expensive. Price above Base.
The price needs 40.5% revenue growth a year for 10 years. Our scenarios assume 14.1–24.4%.
Its past 4 years averaged −9.2% a year.
Value per share
Base case
$0.95
Price used $6.19 is 6.5× this
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
Revenue each value needs
Revenue today $85.7M. The price needs $2.6B by 2036. Base case: $514M. At its recent pace: $32.5M. Bear to Bull: $319M to $763M.
Revenue today $85.7M. The price needs $2.6B by 2036. Base case: $514M. At its recent pace: $32.5M. Bear to Bull: $319M to $763M.
Revenue in 2036
today $85.7M
+$2.1Bmore than the Base case · 5.0×
Value per share · Base case
$0.95
Price $6.19
6.5× this
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 0.0%
- Discount rate
- 8.8%
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 45.65% over the last year. Revenue grew 1,875.05% over the trailing twelve months. Operating margin moved from -2,399.49% to -46.08%. Free cash flow declined 66% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/S range (72nd percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at -46.08% — continued expansion would be needed to justify the premium. Revenue growth of 1,875.05% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Return analysis
Company profile
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
11
Buy
4
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 12, 2026
Q3 FY26 · EPS est $0.06 · Revenue est $72.3M
Q2 FY26
Reported Aug 4, 2026 · Latest
HoverTap a quarter to inspect
Actual
$0.05
Estimate
-$0.01
Year over year
n/m
Vs prior quarter
n/m
3 beats · 1 miss in the last 4 quarters
Institutional Sentiment
Precigen, Inc. · PGEN
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.